CATXPerspective Therapeutics, Inc.

Sign up free
⚡

Perspective Therapeutics Presents Promising - GlobeNewswire

GlobeNewswire · Nov 6, 5:00 PM

Market reactionShares fell 15% on Nov 3.

IntactLast material event Sep 14, 2026 · Updated Oct 24, 2026

VMT-α-NET shows sustained disease control; Phase 3 initiation expected in 2027

Perspective Therapeutics is a clinical-stage company developing VMT-α-NET, a radioactive drug that targets neuroendocrine tumors, along with treatments for melanoma and other solid tumors; none is approved.

Perspective's case rests on lead-212 therapy VMT-α-NET advancing in neuroendocrine tumors. Full Cohort 2 responses and sustained disease control support development, although kidney events need longer follow-up. Phase 3 initiation is now expected in 2027 after FDA discussions. VMT01 and PSV359 provide additional opportunities, including PSV359's Fast Track designation. Management expects existing funds to support planned milestones into late 2027; funding and manufacturing execution remain important.

Thesis checklist

1 risk needs attention

Select a row for evidence
VMT-α-NET responses hold up with longer follow-upSupportedNext: Further response confirmation, cohort-specific durability, and longer kidney follow-up.

Why it is in this state

The evidence, what would weaken it and the source filing

Phase 3 design agreed and sites active around year-endAt riskNext: FDA feedback on the proposed dose and design, followed by site activation and trial initiation.

Why it is in this state

The evidence, what would weaken it and the source filing

PSV359 and VMT01 add second programsAwaiting evidenceNext: VMT01 combination follow-up in late 2026 and PSV359's planned clinical update in 2027.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash lasts into late 2027SupportedNext: An updated cash balance, spending outlook, and funding plan as pivotal and manufacturing commitments become clearer.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

FDA alignment and VMT-α-NET pivotal launch

Tests: Phase 3 design agreed and sites active around year-end

Preparations around year-end 2026; Phase 3 initiation expected in 2027 after FDA discussions.

Will FDA feedback permit the proposed pivotal plan and site activation without further delays?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentClinical
-6.5%Sep 14, 2026

VMT-α-NET shows sustained disease control; Phase 3 initiation expected in 2027

IntactClinical
-4.2%Sep 8, 2026

Alpha-particle radiotherapy for NETs shows 43% responses and deepening durability; Phase 3 design and regulatory alignment will determine if the data translates to approval

IntactRegulatory
+3.4%Aug 3, 2026

Alpha-particle radiopharmaceutical platform with 43% ORR in NETs and melanoma activity both early-stage; registration path for VMT-NET depends on FDA alignment

IntactClinical
+4.9%Jul 1, 2026

Alpha-radiotherapy in NETs posts 43% ORR with clean renal safety — registration pathway hinges on FDA alignment

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Melanoma· unresectable or metastatic, MC1R-positive
VMT01 · 1 upcoming
Phase 1/2a Data: Interim
late 2026
SSTR2-positive neuroendocrine tumors
VMT-NET · 3 upcoming · 2 completed
End-of-Phase Meeting
Q1 2027
Data: Long-term
2027
Phase 3 Study Initiation
Year-end 20262027
N/A
Manufacturing · 1 upcoming
Chicago site construction completion
2026early 2027
Multiple solid tumors
PSV359 · 1 upcoming
Phase 1/2a Data: Interim
Early 20262027
Medullary thyroid cancer
CCK2R81 · 1 upcoming
evaluation
TBD
Melanoma· unresectable or metastatic
VMT01 · 1 completed
Phase 1/2a dose escalation and potential combo expansion
Reported Aug 10, 2026
Melanoma
VMT01/02 · 1 completed
Data: Interim
Reported Jul 1, 2026
Melanoma· MC1R-positive
VMT01 · 1 completed
Data
Reported Jul 1, 2026
Prostate cancer
PSV4XX · 1 completed
Study Initiation
Reported Jul 3, 2025

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Perspective Therapeutics (CATX) investment thesis intact?
Yes. Readouts currently rates the Perspective Therapeutics Thesis Intact. VMT-α-NET shows sustained disease control; Phase 3 initiation expected in 2027.
What is the next catalyst for Perspective Therapeutics (CATX)?
The next dated event is Phase 1/2a interim results for VMT01, expected late 2026, as stated by the company.
How long will Perspective Therapeutics' cash last?
Perspective Therapeutics has said its cash will fund operations into late 2027 (guidance as of August 10, 2026).

Other companies we cover in these diseases

Solid tumors
NextCure (NXTC)

Disease areas: Lung cancer, Gastrointestinal cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

13 peers tracked

For informational purposes only—not investment advice. Always conduct your own research before making investment decisions.

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.